vs
Side-by-side financial comparison of Hologic (HOLX) and Simpson Manufacturing Co., Inc. (SSD). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $588.0M, roughly 1.8× Simpson Manufacturing Co., Inc.). Hologic runs the higher net margin — 17.1% vs 15.0%, a 2.1% gap on every dollar of revenue. On growth, Simpson Manufacturing Co., Inc. posted the faster year-over-year revenue change (9.1% vs 2.5%). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs -0.8%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Simpson Manufacturing Company is a leading building materials manufacturer in the United States that produces structural connectors, fasteners, anchors, and products for new construction and retrofitting.
HOLX vs SSD — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $588.0M |
| Net Profit | $179.1M | $88.2M |
| Gross Margin | 56.0% | 45.2% |
| Operating Margin | 22.6% | 19.5% |
| Net Margin | 17.1% | 15.0% |
| Revenue YoY | 2.5% | 9.1% |
| Net Profit YoY | -10.9% | 13.3% |
| EPS (diluted) | $0.79 | $2.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $588.0M | ||
| Q4 25 | $1.0B | $539.3M | ||
| Q3 25 | $1.0B | $623.5M | ||
| Q2 25 | $1.0B | $631.1M | ||
| Q1 25 | $1.0B | $538.9M | ||
| Q4 24 | $1.0B | $517.4M | ||
| Q3 24 | $988.0M | $587.2M | ||
| Q2 24 | $1.0B | $597.0M |
| Q1 26 | — | $88.2M | ||
| Q4 25 | $179.1M | $56.2M | ||
| Q3 25 | $187.2M | $107.4M | ||
| Q2 25 | $194.9M | $103.5M | ||
| Q1 25 | $-17.4M | $77.9M | ||
| Q4 24 | $201.0M | $55.4M | ||
| Q3 24 | $178.6M | $93.5M | ||
| Q2 24 | $194.5M | $97.8M |
| Q1 26 | — | 45.2% | ||
| Q4 25 | 56.0% | 43.4% | ||
| Q3 25 | 55.6% | 46.4% | ||
| Q2 25 | 56.3% | 46.7% | ||
| Q1 25 | 37.5% | 46.8% | ||
| Q4 24 | 56.8% | 44.0% | ||
| Q3 24 | 56.4% | 46.8% | ||
| Q2 24 | 55.4% | 46.7% |
| Q1 26 | — | 19.5% | ||
| Q4 25 | 22.6% | 13.9% | ||
| Q3 25 | 22.6% | 22.6% | ||
| Q2 25 | 24.9% | 22.2% | ||
| Q1 25 | -0.7% | 19.0% | ||
| Q4 24 | 22.5% | 14.8% | ||
| Q3 24 | 23.3% | 21.3% | ||
| Q2 24 | 24.1% | 22.1% |
| Q1 26 | — | 15.0% | ||
| Q4 25 | 17.1% | 10.4% | ||
| Q3 25 | 17.8% | 17.2% | ||
| Q2 25 | 19.0% | 16.4% | ||
| Q1 25 | -1.7% | 14.5% | ||
| Q4 24 | 19.7% | 10.7% | ||
| Q3 24 | 18.1% | 15.9% | ||
| Q2 24 | 19.2% | 16.4% |
| Q1 26 | — | $2.13 | ||
| Q4 25 | $0.79 | $1.34 | ||
| Q3 25 | $0.84 | $2.58 | ||
| Q2 25 | $0.86 | $2.47 | ||
| Q1 25 | $-0.08 | $1.85 | ||
| Q4 24 | $0.87 | $1.31 | ||
| Q3 24 | $0.75 | $2.21 | ||
| Q2 24 | $0.82 | $2.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $341.0M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | $2.1B |
| Total Assets | $9.2B | $3.0B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $341.0M | ||
| Q4 25 | $2.4B | $384.1M | ||
| Q3 25 | $2.2B | $297.3M | ||
| Q2 25 | $1.9B | $190.4M | ||
| Q1 25 | $1.6B | $150.3M | ||
| Q4 24 | $2.0B | $239.4M | ||
| Q3 24 | $2.3B | $339.4M | ||
| Q2 24 | $2.4B | $354.9M |
| Q1 26 | — | — | ||
| Q4 25 | $2.5B | $300.0M | ||
| Q3 25 | $2.5B | $371.3M | ||
| Q2 25 | $2.5B | $376.9M | ||
| Q1 25 | $2.5B | $382.5M | ||
| Q4 24 | $2.5B | $388.1M | ||
| Q3 24 | $2.5B | $393.8M | ||
| Q2 24 | $2.5B | $399.4M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $5.2B | $2.0B | ||
| Q3 25 | $5.0B | $2.0B | ||
| Q2 25 | $4.8B | $1.9B | ||
| Q1 25 | $4.6B | $1.9B | ||
| Q4 24 | $4.8B | $1.8B | ||
| Q3 24 | $5.1B | $1.9B | ||
| Q2 24 | $5.0B | $1.8B |
| Q1 26 | — | $3.0B | ||
| Q4 25 | $9.2B | $3.1B | ||
| Q3 25 | $9.0B | $3.0B | ||
| Q2 25 | $8.8B | $3.0B | ||
| Q1 25 | $8.5B | $2.8B | ||
| Q4 24 | $8.7B | $2.7B | ||
| Q3 24 | $9.2B | $2.9B | ||
| Q2 24 | $8.9B | $2.8B |
| Q1 26 | — | — | ||
| Q4 25 | 0.48× | 0.15× | ||
| Q3 25 | 0.50× | 0.19× | ||
| Q2 25 | 0.52× | 0.20× | ||
| Q1 25 | 0.55× | 0.21× | ||
| Q4 24 | 0.53× | 0.21× | ||
| Q3 24 | 0.49× | 0.21× | ||
| Q2 24 | 0.51× | 0.23× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | — |
| Free Cash FlowOCF − Capex | $215.2M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $229.9M | $155.7M | ||
| Q3 25 | $355.1M | $170.2M | ||
| Q2 25 | $343.3M | $125.2M | ||
| Q1 25 | $169.4M | $7.6M | ||
| Q4 24 | $189.3M | $115.8M | ||
| Q3 24 | $367.0M | $103.3M | ||
| Q2 24 | $405.8M | $111.1M |
| Q1 26 | — | — | ||
| Q4 25 | $215.2M | $119.0M | ||
| Q3 25 | $341.4M | $133.9M | ||
| Q2 25 | $330.5M | $87.3M | ||
| Q1 25 | $153.9M | $-42.6M | ||
| Q4 24 | $172.5M | $60.3M | ||
| Q3 24 | $350.6M | $58.1M | ||
| Q2 24 | $385.3M | $70.9M |
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | 22.1% | ||
| Q3 25 | 32.5% | 21.5% | ||
| Q2 25 | 32.3% | 13.8% | ||
| Q1 25 | 15.3% | -7.9% | ||
| Q4 24 | 16.9% | 11.7% | ||
| Q3 24 | 35.5% | 9.9% | ||
| Q2 24 | 38.1% | 11.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 6.8% | ||
| Q3 25 | 1.3% | 5.8% | ||
| Q2 25 | 1.3% | 6.0% | ||
| Q1 25 | 1.5% | 9.3% | ||
| Q4 24 | 1.6% | 10.7% | ||
| Q3 24 | 1.7% | 7.7% | ||
| Q2 24 | 2.0% | 6.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | 2.77× | ||
| Q3 25 | 1.90× | 1.58× | ||
| Q2 25 | 1.76× | 1.21× | ||
| Q1 25 | — | 0.10× | ||
| Q4 24 | 0.94× | 2.09× | ||
| Q3 24 | 2.05× | 1.10× | ||
| Q2 24 | 2.09× | 1.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
SSD
Segment breakdown not available.
